Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse.
Tyagi
Vineet
V
Department of Pediatrics and Neonatology, St Stephen's Hospital, Tis Hazari, Delhi, India.
Singh
Saroj K
SK
Sawhney
Ashu
A
Taneja
Vikas
V
Puliyel
Jacob M
JM
D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006509:Hepatitis B / Q000150:complications / Q000191:economics* / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000191:economics*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007194:India / Q000453:epidemiology; D014611:Vaccination / Q000191:economics*
D017325:Hepatitis B Vaccines